Comparative Analysis of the Efficiency and Safety of Pantoprazole, Omeprazole and Rabeprazole In Patient Care: A Systematic Review of Clinical Trials and Pharmacological Studies

Background: Proton pump inhibitors (PPIs) represent the most effective class of acid-suppressive medications, with pantoprazole, omeprazole and rabeprazole being among the most commonly prescribed. Despite their widespread use, comparative effectiveness and safety profiles require systematic evaluation. Objective: To conduct a comprehensive systematic review comparing the efficiency and safety of pantoprazole, omeprazole, and rabeprazole in various clinical conditions based on available clinical trials and pharmacological studies. Methods: A systematic literature search was conducted across PubMed, Cochrane Library, and EMBASE databases for studies published between 2010-2024. Inclusion criteria encompassed randomized controlled trials, comparative studies, and pharmacological analyses comparing at least two of the three PPIs. Primary outcomes included healing rates for peptic ulcers and gastroesophageal reflux disease (GERD), while secondary outcomes focused on adverse events and drug interactions. Results: Seventy-three studies met inclusion criteria, representing 15,847 patients across various indications. All three PPIs demonstrated comparable efficacy in healing peptic ulcers (85-92% healing rates at 4-8 weeks) and managing GERD symptoms (78-85% symptom resolution). Pantoprazole showed superior stability in acidic environments and reduced drug interaction potential. Omeprazole demonstrated the most extensive clinical experience but higher interaction risks with CYP2C19 substrates. Rabeprazole exhibited faster onset of action and consistent efficacy across CYP2C19 genotypes. Conclusions: While all three PPIs show similar therapeutic efficacy, important differences exist in pharmacokinetic properties, drug interactions, and specific clinical scenarios. Selection should be individualized based on patient-specific factors, comedications, and clinical context.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-10-13
DOI
https://doi.org/10.5281/zenodo.17342304
Primary Topic
Gastroesophageal reflux and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative Analysis of the Efficiency and Safety of Pantoprazole, Omeprazole and Rabeprazole In Patient Care: A Systematic Review of Clinical Trials and Pharmacological Studies

Zenodo (CERN European Organization for Nuclear Research)
Gastroesophageal reflux and treatments
article

Comparative Analysis of the Efficiency and Safety of Pantoprazole, Omeprazole and Rabeprazole In Patient Care: A Systematic Review of Clinical Trials and Pharmacological Studies

article en

Abstract

Background: Proton pump inhibitors (PPIs) represent the most effective class of acid-suppressive medications, with pantoprazole, omeprazole and rabeprazole being among the most commonly prescribed. Despite their widespread use, comparative effectiveness and safety profiles require systematic evaluation. Objective: To conduct a comprehensive systematic review comparing the efficiency and safety of pantoprazole, omeprazole, and rabeprazole in various clinical conditions based on available clinical trials and pharmacological studies. Methods: A systematic literature search was conducted across PubMed, Cochrane Library, and EMBASE databases for studies published between 2010-2024. Inclusion criteria encompassed randomized controlled trials, comparative studies, and pharmacological analyses comparing at least two of the three PPIs. Primary outcomes included healing rates for peptic ulcers and gastroesophageal reflux disease (GERD), while secondary outcomes focused on adverse events and drug interactions. Results: Seventy-three studies met inclusion criteria, representing 15,847 patients across various indications. All three PPIs demonstrated comparable efficacy in healing peptic ulcers (85-92% healing rates at 4-8 weeks) and managing GERD symptoms (78-85% symptom resolution). Pantoprazole showed superior stability in acidic environments and reduced drug interaction potential. Omeprazole demonstrated the most extensive clinical experience but higher interaction risks with CYP2C19 substrates. Rabeprazole exhibited faster onset of action and consistent efficacy across CYP2C19 genotypes. Conclusions: While all three PPIs show similar therapeutic efficacy, important differences exist in pharmacokinetic properties, drug interactions, and specific clinical scenarios. Selection should be individualized based on patient-specific factors, comedications, and clinical context.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 36%
Gastroesophageal reflux and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.